It was shown that irisin levels were lower in patients with both postmenopausal osteoporosis and sarcopenia than in healthy subjects, so scientific evidence to date shows that irisin could be used as a biomarker for these two diseases. This evidence concerns the gene FNDC5 and sarcopenia.